Haoyoubo announcement, the company's stock trading on October 31, 2024, and November 1, 2024, the closing prices deviated cumulatively by 30% over two consecutive trading days, belonging to abnormal stock trading volatility. The company is mainly engaged in the research and development, production, and sales of in vitro diagnostic reagents, with products mainly for testing various diseases in the two major areas of allergies and autoimmunity. As of the date of this announcement, the company's production and operation are normal, and there have been no significant changes in the internal and external operating environment. In addition, the company's controlling shareholder Hairuixiangtian and its concerted action Suzhou Wairun, the actual controllers JOHN LI, WEIJUN LI, Chen Tao, and Huirunrongkang and its concerted action Shanrunzhengan signed the "Share Transfer Agreement," stipulating that Hairuixiangtian will transfer its 18,670,878 unrestricted shares of the company to Huirunrongkang, accounting for 29.99% of the total shares after deducting the number of shares in the company's repurchase special account. After this share transfer is completed, the company's controlling shareholder will change from Hairuixiangtian to Huirunrongkang, and the actual controllers will change from JOHN LI, WEIJUN LI, Chen Tao to Sino Biopharmaceutical Limited.